We’re Stronger Together
With your help, we can make ambitious innovations in clinical care and education for our community.
Adult Open Studies
LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection Protocol
Champions Oncology
Refer to separate attachment for list of "Tumors of High Interest"; this is included within the LLUCC Biospecimen Laboratory study above
SWOG-NRG-BR009
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/ HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Syndevrx SDX-0103
A Phase 1b/2 Study Assessing The Safety And Efficacy of Evexomostat (Sdx-7320) In Combination With The Pi3kα Inhibitor alpelisib (Piqray®) Plus Fulvestrant In Postmenopausal Women At Risk For Hyperglycemia With Advanced Breast Cancer And A Pik3ca Mutation Who Have Progressed On Or Following Endocrine Therapy Plus A Cdk4/6 Inhibitor
EMBER-4 E-Lilly – J2J-MC-JZLH
A Randomized, Open Label, Phase 3 Study of Adjuvant imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have previously received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2-Early Breast Cancer with an Increased Risk of Recurrence.
https://classic.clinicaltrials.gov/ct2/show/NCT05514054
https://classic.clinicaltrials.gov/ct2/show/NCT05514054
SWOG -S2212
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast (SCARLET), A Randomized Phase III Study
https://classic.clinicaltrials.gov/ct2/show/NCT05929768
https://classic.clinicaltrials.gov/ct2/show/NCT05929768
SWOG-S2206
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
https://clinicaltrials.gov/study/NCT06058377
https://clinicaltrials.gov/study/NCT06058377
Alliance-A012103
OptimICE PCR: De-Escalation of Therapy in Early -Stage TNBC Patients Who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
https://clinicaltrials.gov/ct2/show/NCT05812807
https://clinicaltrials.gov/ct2/show/NCT05812807
4T-22-2-MAGESTIC
Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –( MAGESTIC Trial: MiRNA in detecting Active Germ Cell tumors in Early Suspected and metastaTIC disease trial)
https://clinicaltrials.gov/study/NCT06060873/a>
https://clinicaltrials.gov/study/NCT06060873/a>
Esophageal
Radiation Medicine
A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer
https://clinicaltrials.gov/ct2/show/NCT01684904
https://clinicaltrials.gov/ct2/show/NCT01684904
Pancreas
INV INT-Pancreatic - 5170277
A Phase II Trial of Pre-operative Chemotherapy (with Gemcitabine and Nab-paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma
https://www.clinicaltrials.gov/ct2/show/NCT03492671
https://www.clinicaltrials.gov/ct2/show/NCT03492671
Liver
Radiation Medicine
Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases
https://clinicaltrials.gov/ct2/show/NCT01697371
https://clinicaltrials.gov/ct2/show/NCT01697371
NSCLC
SWOG-LUNGMAP
A Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
https://www.clinicaltrials.gov/ct2/show/NCT02154490
https://www.clinicaltrials.gov/ct2/show/NCT02154490
NSCLC
SWOG-A081801
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
https://clinicaltrials.gov/ct2/show/NCT04267848
https://clinicaltrials.gov/ct2/show/NCT04267848
NSCLC
SWOG-S1900G
A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP-Sub-Study)
https://clinicaltrials.gov/study/NCT05642572
https://clinicaltrials.gov/study/NCT05642572
NSCLC
SWOG-S1900J
A Phase II Study of Amivantamab SC (Subcutaneous) Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Lung Cancer (Lung-MAP Sub-Study)
https://clinicaltrials.gov/study/NCT06116682
https://clinicaltrials.gov/study/NCT06116682
ARETEMIDE
LUNG - 02
A Phase III, Randomized, double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARETEMIDE-Lung02)
https://clinicaltrials.gov/study/NCT06692738?viewType=Card&cond=ARTEMIDE-Lung02&rank=1
https://clinicaltrials.gov/study/NCT06692738?viewType=Card&cond=ARTEMIDE-Lung02&rank=1
NSCLC
SWOG-S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Ce4miplimab (REGN2810) for Participants previously Treated with Platinumab-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP)
https://clinicaltrials.gov/study/NCT06616584?term=S1800E&rank=1
https://clinicaltrials.gov/study/NCT06616584?term=S1800E&rank=1
TROPION
LUNG - 17
A Phase III, Randomized,Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung 17)
https://clinicaltrials.gov/study/NCT07291037?term=D763QC00001&viewType=Card&rank=1
https://clinicaltrials.gov/study/NCT07291037?term=D763QC00001&viewType=Card&rank=1
Castle Biosciences-CBI-2019-SLNBprosp-001
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes DECIDE
https://clinicaltrials.gov/ct2/show/NCT02355587
https://clinicaltrials.gov/ct2/show/NCT02355587
COG-AGCT1532
A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with Intermediate and poor-risk metastatic germ cell tumors (Ages 26+ - Primary tumor arising in testis, ovary, retro-peritoneum or mediastinum)
AMGEN-20190135-H
A Phase 1b Study Evaluating the Safety, Tolerability and Efficacy of AMG 510 (pINN Sotorasib) in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (Codebreak 101 Subprotocol H)
https://clinicaltrials.gov/study/NCT04185883
https://clinicaltrials.gov/study/NCT04185883
INV-INT-PRESERVE
Phase II Randomized Single-Blinded Trial of Patient Reported Experiences with Sparing ExteRnal Oblique Fascia Vs Standard Inguinal OrchiEctomy (PRESERVE Trial)
https://clinicaltrials.gov/study/NCT06828185
https://clinicaltrials.gov/study/NCT06828185
PTLD
ATARA - ATA129-EBV-302
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
https://clinicaltrials.gov/ct2/show/NCT03394365
https://clinicaltrials.gov/ct2/show/NCT03394365
P-CD19CD20-ALLO1
Open-Label, Multicenter, Phase I Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B Cell Malignancies
https://clinicaltrials.gov/study/NCT06014762?term=P-CD19CD20-ALLO1
https://clinicaltrials.gov/study/NCT06014762?term=P-CD19CD20-ALLO1
ALLO-T-DART-NYMC-598
A Phase 1 Trial of Targeted Immunotherapy with Daratunumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogenic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) (ALLO-T-DART)
https://clinicaltrials.gov/study/NCT04972942?term=ALLO-T-DART
https://clinicaltrials.gov/study/NCT04972942?term=ALLO-T-DART
NYMC-600
A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with either Renal and/or Pulmonary dysfunction with Either Refractory or Progressive Disease Following Defibrotide
https://clinicaltrials.gov/study/NCT05987124?term=NYMC-600
https://clinicaltrials.gov/study/NCT05987124?term=NYMC-600
BB2121-EAP-001
Expanded Access Protocol (DAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release
https://clinicaltrials.gov/study/NCT04771078?term=BB2121-EAP-001
https://clinicaltrials.gov/study/NCT04771078?term=BB2121-EAP-001
JCAR017-EAP-001
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
https://clinicaltrials.gov/study/NCT04400591?term=JCAR017-EAP-001
https://clinicaltrials.gov/study/NCT04400591?term=JCAR017-EAP-001
MAP–CCTL019B20031
Managed Access Program (MAP) Cohort Treatment Plan CCTL019B20031 to provide access for patients with out of specification leukapheresis product and/or out of specification manufactured tisagenlecleucel (CTL019, Kymriah)
https://clinicaltrials.gov/study/NCT03601442?term=NCT03601442
https://clinicaltrials.gov/study/NCT03601442?term=NCT03601442
NOVARTIS-CYTB323J12201
Phase 2, Adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)
https://clinicaltrials.gov/study/NCT06581198?viewType=Card&limit=10&sort=@relevance&term=Novartis%20CYTB323J12201&rank=1
https://clinicaltrials.gov/study/NCT06581198?viewType=Card&limit=10&sort=@relevance&term=Novartis%20CYTB323J12201&rank=1
Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050